Therefore, the clinical outcome of ICOS agonist therapy in cancer immunotherapy may face challenges due to the dual nature of the ICOS/ICOSL axis as either enhancer of antitumor T-cell reactions or inducer of pro-tumor responses, depending on the critical expression and functional role of ICOS on Tregs and other T-cell subtypes. Here, ICOS is linked to cancer.